Clinical trials
Phase 3 Myelodysplastic Syndromes trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Terminated | 7 |
| Active, not recruiting | 5 |
| Recruiting | 2 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 5 |
| Children's Oncology Group | 3 |
| Astex Pharmaceuticals, Inc. | 2 |
| Novartis Pharmaceuticals | 2 |
| Takeda | 2 |
| AbbVie | 1 |
| Bristol-Myers Squibb | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Gilead Sciences | 1 |
| Kiadis Pharma | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myelodysplastic Syndromes | 28 |
| Leukemia, Myeloid, Acute | 9 |
| Leukemia, Myelomonocytic, Chronic | 9 |
| Anemia | 6 |
| Myeloproliferative Disorders | 6 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 |
| Anemia, Refractory, with Excess of Blasts | 5 |
| Leukemia | 5 |
| Lymphoma | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
Trials
Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.